Sir Stephen Jackson FMedSci FRS
Steve Jackson has unravelled the complex processes by which cells protect their genetic information. His research has also led to a new type of cancer drug that is being used to treat ovarian cancer and that holds promise for treating various other intractable cancers with minimal side effects.
He discovered various DNA repair proteins and showed how they function in yeast and human cells. He also connected their dysfunction to cancer, developmental defects, ageing and immunodeficiency. Based on his academic work, Steve founded a company that developed various drugs with anti-cancer potential; several are in clinical trials by a large pharmaceutical firm and one, Olaparib, has become a registered drug in the European Union and United States.
He has since launched a new company developing small molecules that intervene in DNA repair pathways. Steve was the youngest person to be elected to a chair at the University of Cambridge since Isaac Newton: amongst other prizes, he won the inaugural BBSRC Innovator of the Year Award in 2009 and the Royal Society Buchanan Medal in 2011.
Professor of Biology, University of Cambridge
Associate Faculty Member, Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge
Chief Scientific Officer, MISSION Therapeutics Ltd
Senior Group Leader, Cancer Research UK Cambridge Institute, University of Cambridge
Interest and expertise
- Biochemistry and molecular cell biology
- Cell biology (incl molecular cell biology)
DNA repair, Basic cancer research, Molecular biology, Cancer therapy